STD Diagnostics Market - Growth, Trends, and Forecast (2019 - 2024)
NEW YORK, Sept. 11, 2019 /PRNewswire/ --
Market Overview
The major shift from conventional technologies to molecular diagnostics for the diagnosis of STD's is the major breakthrough for the growth of the market. Additionally, the growing prevalence of STD's globally increases patient awareness through education campaigns and growing government initiatives are anticipated to drive market growth. According to UNAIDS in 2018, there were 37.9 million [32.7 million–44.0 million] people living with HIV. Furthermore, the increasing population having multiple casual sex partners is also fueling market growth.
Read the full report: https://www.reportlinker.com/p05815042/?utm_source=PRN
Scope of the Report
STD's (Sexually Transmitted Diseases) are the infections which transmit from one person to another during oral, anal and vaginal sex. Bacteria, parasites, yeast, and viruses are the main causes of STD's. Most STDs affect both men and women, but in many cases, the health problems they cause can be more severe for women. Rapid and early diagnosis of STDs will limit the effects and progression of the disease. If the STDs are left untreated, it can lead to more serious and long-term health complications.
Key Market Trends
Gonorrhea to dominate the STD Diagnostics Market
Gonorrhea, caused by Neisseria gonorrhoeae, is the second most common bacterial STI and results in substantial morbidity and economic cost worldwide. It is also known as "the clap". According to the European Centre for Disease Prevention and Control, A total of 89,239 cases of gonorrhea were reported by 27 EU/EEA Member States for 2017. The bacteria are mainly found in discharge from the penis and in vaginal fluid. Gonorrhoea is easily passed between people through unprotected vaginal, oral or anal sex. Gonorrhoea can be easily diagnosed by testing a sample of discharge picked up using a swab. Gonorrhea is also diagnosed by physical examination, including pelvic exam in young women, and thorough medical history, plus laboratory testing of cervical, vaginal or penile secretions.
North America holds largest share in Global STD Diagnostics Market
The global sexually transmitted diseases diagnostics market is dominated by North America, owing to the high prevalence of the STD's. According to the Centers for Disease Control and Prevention's Sexually Transmitted Infections Surveillance Report, the rate of sexually transmitted infections is steadily increasing, with an estimated 1.7 million cases of chlamydia and more than 500,000 cases of gonorrhea in the US in 2017 alone. Additionally, the presence of public healthcare insurance plans is fostering healthcare consciousness amongst people, availability of FDA-approved advanced sexually transmitted disease testing devices, high healthcare expenditure is likely to boost the market growth in North America.
Competitive Landscape
Key players in STD diagnostics market are Abbott Laboratories, MedMira Inc, Qaigen Inc, Cepheid (Danaher Corporation), F. Hoffmann-La Roche AG, Diasorin S.p.A, bioMeriuex, Hologic, Inc, Bio-Rad Laboratories, Inc., amongst others. These companies focus on the partnership and product/technology licensing opportunities in the sexually transmitted diseases diagnostics industry. In May 2019, the US Food and Drug Administration (FDA) has cleared two tests "The Aptima Combo 2 Assay (Hologic Inc) and the Xpert CT/NG (Cepheid)" to detect Chlamydia trachomatis and Neisseria gonorrhoeae from throat and rectum samples.
Reasons to Purchase this report:
- The market estimate (ME) sheet in Excel format
- Report customization as per the client's requirements
- 3 months of analyst support
Read the full report: https://www.reportlinker.com/p05815042/?utm_source=PRN
About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001
SOURCE Reportlinker
Share this article